| First Author | Seachrist DD | Year | 2019 |
| Journal | Endocrinology | Volume | 160 |
| Issue | 5 | Pages | 1097-1110 |
| PubMed ID | 30874767 | Mgi Jnum | J:273698 |
| Mgi Id | MGI:6294348 | Doi | 10.1210/en.2019-00015 |
| Citation | Seachrist DD, et al. (2019) The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer. Endocrinology 160(5):1097-1110 |
| abstractText | Activins and inhibins are closely related protein heterodimers with a similar tissue distribution; however, these two complexes have opposing functions in development and disease. Both are secreted cytokine hormones, with activin the primary inducer of downstream signaling cascades and inhibin acting as a rheostat that exquisitely governs activin function. Adding to the complexity of activin signaling, follistatin, a highly glycosylated monomeric protein, binds activin with high affinity and restrains downstream pathway activation but through a mechanism distinct from that of inhibin. These three proteins were first identified as key ovarian hormones in the pituitary-gonadal axis that direct the synthesis and secretion of FSH from the pituitary, hence controlling folliculogenesis. Research during the past 30 years has expanded the roles of these proteins, first by discovering the ubiquitous expression of the trio and then by implicating them in a wide array of biological functions. In concert, these three hormones govern tissue development, homeostasis, and disease in multiple organ systems through diverse autocrine and paracrine mechanisms. In the present study, we have reviewed the actions of activin and its biological inhibitors, inhibin, and follistatin, in mammary gland morphogenesis and cancer. |
